{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:55:33Z","timestamp":1775080533610,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009392","name":"Prince Sattam bin Abdulaziz University","doi-asserted-by":"publisher","award":["PSAU\/2025\/R\/1446"],"award-info":[{"award-number":["PSAU\/2025\/R\/1446"]}],"id":[{"id":"10.13039\/100009392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10822-025-00599-z","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:32:12Z","timestamp":1745555532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anticancer potential of novel benzothiazolyl piperidine-3-carboxamide derivatives as CDKs and VEGFR2 multi-target kinase inhibitors"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4188-5592","authenticated-orcid":false,"given":"Obaid","family":"Afzal","sequence":"first","affiliation":[]},{"given":"Ali","family":"Altharawi","sequence":"additional","affiliation":[]},{"given":"Safar M.","family":"Alqahtani","sequence":"additional","affiliation":[]},{"given":"Manal A.","family":"Alossaimi","sequence":"additional","affiliation":[]},{"given":"Taibah","family":"Aldakhil","sequence":"additional","affiliation":[]},{"given":"Abdulmalik S. A.","family":"Altamimi","sequence":"additional","affiliation":[]},{"given":"Alhumaidi","family":"Alabbas","sequence":"additional","affiliation":[]},{"given":"Mubarak A.","family":"Alamri","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"issue":"5","key":"599_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.gendis.2020.09.002","volume":"8","author":"A Upadhyay","year":"2021","unstructured":"Upadhyay A (2021) Cancer: an unknown territory; rethinking before going ahead. Genes Dis 8(5):655\u2013661. https:\/\/doi.org\/10.1016\/j.gendis.2020.09.002","journal-title":"Genes Dis"},{"issue":"3","key":"599_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"599_CR3","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S1470-2045(22)00488-0","volume":"23","author":"S Alhomoud","year":"2022","unstructured":"Alhomoud S, Al-Othman S, Al-Madouj A, Al Homsi M, AlSaleh K, Balaraj K, Alajmi A, Basu P, Al-Zahrani A (2022) Progress and remaining challenges for cancer control in the Gulf Cooperation Council. Lancet Oncol 23(11):e493\u2013e501. https:\/\/doi.org\/10.1016\/S1470-2045(22)00488-0","journal-title":"Lancet Oncol"},{"issue":"2","key":"599_CR4","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","volume":"8","author":"C de Martel","year":"2020","unstructured":"de Martel C, Georges D, Bray F, Ferlay J, Clifford GM (2020) Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 8(2):e180\u2013e190. https:\/\/doi.org\/10.1016\/S2214-109X(19)30488-7","journal-title":"Lancet Glob Health"},{"issue":"1","key":"599_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5732\/cjc.010.10553","volume":"30","author":"L Yan","year":"2011","unstructured":"Yan L, Rosen N, Arteaga C (2011) Targeted cancer therapies. Chin J Cancer 30(1):1\u20134. https:\/\/doi.org\/10.5732\/cjc.010.10553","journal-title":"Chin J Cancer"},{"key":"599_CR6","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3389\/fphar.2018.01300","volume":"9","author":"L Falzone","year":"2018","unstructured":"Falzone L, Salomone S, Libra M (2018) Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol 9:1300. https:\/\/doi.org\/10.3389\/fphar.2018.01300","journal-title":"Front Pharmacol"},{"key":"599_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nrg2707","volume":"11","author":"P Lahiry","year":"2010","unstructured":"Lahiry P, Torkamani A, Schork NJ, Hegele RA (2010) Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet 11:60\u201374. https:\/\/doi.org\/10.1038\/nrg2707","journal-title":"Nat Rev Genet"},{"key":"599_CR8","doi-asserted-by":"publisher","first-page":"105463","DOI":"10.1016\/j.phrs.2024.107059","volume":"165","author":"R Roskoski","year":"2021","unstructured":"Roskoski R (2021) Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. Pharmacol Res 165:105463. https:\/\/doi.org\/10.1016\/j.phrs.2024.107059","journal-title":"Pharmacol Res"},{"issue":"2","key":"599_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","volume":"65","author":"CC Ayala-Aguilera","year":"2022","unstructured":"Ayala-Aguilera CC, Valero T, Lorente-Mac\u00edas \u00c1, Baillache DJ, Croke S, Unciti-Broceta A (2022) Small molecule kinase inhibitor drugs (1995\u20132021): medical indication, pharmacology, and synthesis. J Med Chem 65(2):1047\u20131131. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00963","journal-title":"J Med Chem"},{"issue":"9","key":"599_CR10","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1021\/acs.jmedchem.8b01469","volume":"62","author":"S Tadesse","year":"2018","unstructured":"Tadesse S, Caldon EC, Tilley W, Wang S (2018) Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. J Med Chem 62(9):4233\u20134251. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01469","journal-title":"J Med Chem"},{"key":"599_CR11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00280-008-0921-5","volume":"64","author":"A Conroy","year":"2009","unstructured":"Conroy A, Stockett DE, Walker D, Arkin MR, Hoch U, Fox JA, Hawtin RE (2009) SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 64:723\u2013732. https:\/\/doi.org\/10.1007\/s00280-008-0921-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"599_CR12","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1182\/blood-2008-12-190256","volume":"113","author":"R Chen","year":"2009","unstructured":"Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Plunkett W (2009) Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113(19):4637\u20134645. https:\/\/doi.org\/10.1182\/blood-2008-12-190256","journal-title":"Blood"},{"issue":"5","key":"599_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1593\/neo.07136","volume":"9","author":"MA Ali","year":"2007","unstructured":"Ali MA, Choy H, Habib AA, Saha D (2007) SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 9(5):370\u2013381. https:\/\/doi.org\/10.1593\/neo.07136","journal-title":"Neoplasia"},{"issue":"10","key":"599_CR14","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","volume":"15","author":"P Chen","year":"2016","unstructured":"Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He YA, Yu X (2016) Spectrum and degree of CDK drug interactions predicts clinical performance. Mol Cancer Ther 15(10):2273\u20132281. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0300","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"599_CR15","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1021\/jm0305568","volume":"47","author":"RN Misra","year":"2004","unstructured":"Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, Hunt JT, Rawlins DB, Shan W, Ahmed SZ, Qian L (2004) N-(cycloalkylamino) acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 47(7):1719\u20131728. https:\/\/doi.org\/10.1021\/jm0305568","journal-title":"J Med Chem"},{"issue":"1","key":"599_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/14756366.2019.1698036","volume":"35","author":"A Irfan","year":"2020","unstructured":"Irfan A, Batool F, Naqvi SAZ, Islam A, Osman SM, Nocentini A, Alissa SA, Supuran CT (2020) Benzothiazole derivatives as anticancer agents. J Enzyme Inhib Med Chem 35(1):265\u2013279. https:\/\/doi.org\/10.1080\/14756366.2019.1698036","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"599_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.chembiol.2018.10.015","volume":"26","author":"DJ Wood","year":"2019","unstructured":"Wood DJ, Korolchuk S, Tatum NJ, Wang LZ, Endicott JA, Noble ME, Martin MP (2019) Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition. Cell Chem Biol 26(1):121\u2013130. https:\/\/doi.org\/10.1016\/j.chembiol.2018.10.015","journal-title":"Cell Chem Biol"},{"key":"599_CR18","unstructured":"Hilgers MT, Pelletier LA. Structure of CDK4-Cyclin D3 bound to abemaciclib. https:\/\/www.rcsb.org\/structure\/7SJ3"},{"issue":"18","key":"599_CR19","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.1016\/j.bmcl.2012.07.068","volume":"22","author":"J Malmstr\u00f6m","year":"2012","unstructured":"Malmstr\u00f6m J, Viklund J, Slivo C, Costa A, Maudet M, Sandelin C, Hiller G, Olsson LL, Aagaard A, Geschwindner S, Xue Y (2012) Synthesis and structure-activity relationship of 4-(1, 3-benzothiazol-2-yl)-thiophene-2-sulfonamides as cyclin-dependent kinase 5 (cdk5)\/p25 inhibitors. Bioorg Med Chem Lett 22(18):5919\u20135923. https:\/\/doi.org\/10.1016\/j.bmcl.2012.07.068","journal-title":"Bioorg Med Chem Lett"},{"key":"599_CR20","unstructured":"Laursen M, Caing-Carlsson R, Houssari R, Javadi A, Kimbung YR, Murina V, Orozco-Rodriguez JM, Svensson A, Welin M, Logan D, Svensson B, Walse B. Crystal structure of the human CDK7 kinase domain in complex with LDC4297. https:\/\/www.rcsb.org\/structure\/8P4Z"},{"issue":"20","key":"599_CR21","doi-asserted-by":"publisher","first-page":"15189","DOI":"10.1021\/acs.jmedchem.1c01249","volume":"64","author":"B Barlaam","year":"2021","unstructured":"Barlaam B, De Savi C, Dishington A, Drew L, Ferguson AD, Ferguson D, Gu C, Hande S, Hassall L, Hawkins J, Hird AW (2021) Discovery of a series of 7-azaindoles as potent and highly selective CDK9 inhibitors for transient target engagement. J Med Chem 64(20):15189\u201315213. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01249","journal-title":"J Med Chem"},{"issue":"45","key":"599_CR22","doi-asserted-by":"publisher","first-page":"18281","DOI":"10.1073\/pnas.1207759109","volume":"109","author":"M McTigue","year":"2012","unstructured":"McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS (2012) Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. PNAS 109(45):18281\u201318289. https:\/\/doi.org\/10.1073\/pnas.1207759109","journal-title":"PNAS"},{"key":"599_CR23","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177\u20136196. https:\/\/doi.org\/10.1021\/jm051256o","journal-title":"J Med Chem"},{"issue":"1","key":"599_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/17460441.2023.2267015","volume":"19","author":"AA Kaczor","year":"2023","unstructured":"Kaczor AA, Zi\u0119ba A, Matosiuk D (2023) The application of WaterMap-guided structure-based virtual screening in novel drug discovery. Expert Opin Drug Discov 19(1):73\u201383. https:\/\/doi.org\/10.1080\/17460441.2023.2267015","journal-title":"Expert Opin Drug Discov"},{"issue":"2","key":"599_CR25","doi-asserted-by":"publisher","first-page":"132332","DOI":"10.1016\/j.ijbiomac.2024.132332","volume":"270","author":"S Ahmad","year":"2024","unstructured":"Ahmad S, Singh AP, Bano N, Raza K, Singh J, Medigeshi GR, Pandey R, Gautam HK (2024) Integrative analysis discovers Imidurea as dual multitargeted inhibitor of CD69, CD40, SHP2, lysozyme, GATA3, cCBL, and S-cysteinase from SARS-CoV-2 and M. tuberculosis. Int J Biol Macromol 270(2):132332. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.132332","journal-title":"Int J Biol Macromol"},{"key":"599_CR26","doi-asserted-by":"crossref","unstructured":"Bowers KJ, Chow E, Xu H, Dror RO, Eastwood MP, Gregersen BA, Shaw DE (2006) Scalable algorithms for molecular dynamics simulations on commodity clusters. In: Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing, pp. 84-es.","DOI":"10.1145\/1188455.1188544"},{"issue":"1","key":"599_CR27","doi-asserted-by":"publisher","first-page":"133872","DOI":"10.1016\/j.ijbiomac.2024.133872","volume":"276","author":"S Ahmad","year":"2024","unstructured":"Ahmad S, Bano N, Khanna K, Gupta D, Raza K (2024) Reporting multitargeted potency of Tiaprofenic acid against lung cancer: molecular fingerprinting, MD simulation, and MTT-based cell viability assay studies. Int J Biol Macromol 276(1):133872. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.133872","journal-title":"Int J Biol Macromol"},{"key":"599_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2025.2472402","author":"O Afzal","year":"2025","unstructured":"Afzal O, Alamri MA, Altharawi A, Alossaimi MA, Mohamed MA, Altamimi ASA, Asfour HZ, Alhakamy NA, Firoz A (2025) Rational design, docking, simulation, synthesis, and in vitro studies of small benzothiazole molecules as selective BACE1 inhibitors. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2025.2472402","journal-title":"J Biomol Struct Dyn"},{"issue":"2","key":"599_CR29","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14(2):130\u2013146. https:\/\/doi.org\/10.1038\/nrd4504","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"599_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/bmc.3370","volume":"29","author":"K Sharma","year":"2015","unstructured":"Sharma K, Suresh PS, Mullangi R, Srinivas NR (2015) Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors\u2013review of assay methodologies and perspectives. Biomed Chromatogr 29(6):803\u2013834. https:\/\/doi.org\/10.1002\/bmc.3370","journal-title":"Biomed Chromatogr"},{"key":"599_CR31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.ejmech.2016.05.038","volume":"121","author":"O Afzal","year":"2016","unstructured":"Afzal O, Akhtar MS, Kumar S, Ali MR, Jaggi M, Bawa S (2016) Hit to lead optimization of a series of N-[4-(1,3-benzothiazol-2-yl) phenyl] acetamides as monoacylglycerol lipase inhibitors with potential anticancer activity. Eur J Med Chem 121:318\u2013330. https:\/\/doi.org\/10.1016\/j.ejmech.2016.05.038","journal-title":"Eur J Med Chem"},{"issue":"10","key":"599_CR32","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6(10):813\u2013823. https:\/\/doi.org\/10.1038\/nrc1951","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"599_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1021\/cn200100h","volume":"3","author":"AK Ghose","year":"2012","unstructured":"Ghose AK, Herbertz T, Hudkins RL, Dorsey BD, Mallamo JP (2012) Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem Neurosci 3(1):50\u201368. https:\/\/doi.org\/10.1021\/cn200100h","journal-title":"ACS Chem Neurosci"},{"issue":"W1","key":"599_CR34","doi-asserted-by":"publisher","first-page":"W513","DOI":"10.1093\/nar\/gkae303","volume":"52","author":"P Banerjee","year":"2024","unstructured":"Banerjee P, Kemmler E, Dunkel M, Preissner R (2024) ProTox 3.0: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 52(W1):W513\u2013W520. https:\/\/doi.org\/10.1093\/nar\/gkae303","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"599_CR35","doi-asserted-by":"publisher","first-page":"24460","DOI":"10.1038\/srep24460","volume":"6","author":"MA Aziz","year":"2016","unstructured":"Aziz MA, Serya RA, Lasheen DS, Abdel-Aziz AK, Esmat A, Mansour AM, Singab ANB, Abouzid KA (2016) Discovery of potent VEGFR-2 inhibitors based on furopyrimidine and thienopyrimidne scaffolds as cancer targeting agents. Sci Rep 6(1):24460. https:\/\/doi.org\/10.1038\/srep24460","journal-title":"Sci Rep"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00599-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-025-00599-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-025-00599-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:56:35Z","timestamp":1762451795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-025-00599-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["599"],"URL":"https:\/\/doi.org\/10.1007\/s10822-025-00599-z","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}